Simon N. Pimstone is the former CEO of Xenon Pharmaceuticals, where he led the company from 2003 until 2021. With a diverse background in medicine and research, he holds an MBChB from the University of Cape Town, a Ph.D. in...
Simon N. Pimstone is the former CEO of Xenon Pharmaceuticals, where he led the company from 2003 until 2021. With a diverse background in medicine and research, he holds an MBChB from the University of Cape Town, a Ph.D. in cardiovascular genetics from the University of Amsterdam, and a fellowship from the University of British Columbia. Simon's leadership style is underscored by his emphasis on performance-driven outcomes, which was reflected in the company's goals focused on clinical and regulatory milestones. In 2021, his total compensation reached over $1 million, combining a salary of $525,000 and a performance-based bonus, a testament to his role in guiding research initiatives. Notably, he has contributed to advancing treatments for epilepsy, making meaningful strides in improving patient care. His analytical approach and commitment to corporate objectives have resulted in notable achievements at Xenon Pharmaceuticals, helping the company navigate the complexities of the biotech industry and establish itself as a key player in healthcare innovation.